In their pre-Christmas government funding bill, US lawmakers were not in a giving mood when it came to bestowing the Food and Drug Administration with a lot of extra authority to ensure drug sponsors conduct sufficiently diverse clinical trials.
However, they also declined to give industry some safe harbor protections on use of digital health technologies and remuneration to...